 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Kidney Disease / Dialysis
Kidney disease, also known as chronic kidney disease (CKD), occurs when kidneys can no longer remove wastes and extra water from the blood as they should. Kidney disease is most often caused by diabetes or high blood pressure.
[Source: http:// nihseniorhealth.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Kidney Disease Study CSBR759A2201
The purpose of this clinical research study is to find out if one of these two medicines, SBR759 (an investigational drug) or sevelamer HCl (Renagel®) is better at reducing phosphate levels in the blood of participants on dialysis. SBR759 is an “investigational drug” which is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2 Participation Duration: Participants will continue their regular schedule of dialysis treatments. Most of the study procedures will be carried out during their regularly scheduled dialysis appointments at specific centers. Total participation in this study will last for about 12 months. There will be a total of 28 study visits. All will take place during the first dialysis treatment of the week. The first 16 visits and the last 2 visits will occur weekly and all others only once a month. Protocol Number: CSBR759A2201 |
